Lipocine Inc. Files 8-K
Ticker: LPCN · Form: 8-K · Filed: Jun 9, 2025 · CIK: 1535955
| Field | Detail |
|---|---|
| Company | Lipocine Inc. (LPCN) |
| Form Type | 8-K |
| Filed Date | Jun 9, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing, financial-reporting
TL;DR
Lipocine filed an 8-K on 6/9/25. Standard reporting, no major news.
AI Summary
Lipocine Inc. filed an 8-K on June 9, 2025, reporting other events and financial statements. The company, previously known as Marathon Bar Corp until November 30, 2011, is incorporated in Delaware and headquartered in Salt Lake City, Utah. This filing does not appear to contain specific financial transaction details or material events beyond routine reporting.
Why It Matters
This 8-K filing indicates Lipocine Inc. is fulfilling its regulatory reporting obligations. Investors should review the full filing for any specific disclosures that might impact the company's operations or financial standing.
Risk Assessment
Risk Level: low — The filing appears to be routine and does not disclose any significant new risks or material adverse events.
Key Players & Entities
- Lipocine Inc. (company) — Registrant
- Marathon Bar Corp (company) — Former company name
- 20111130 (date) — Date of former company name change
- 675 Arapeen Drive, Suite 202 (location) — Principal executive offices address
- Salt Lake City, Utah (location) — Principal executive offices city and state
- 801-994-7383 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing for Lipocine Inc.?
The 8-K filing on June 9, 2025, is for reporting 'Other Events' and 'Financial Statements and Exhibits' as per SEC regulations.
When did Lipocine Inc. change its name from Marathon Bar Corp?
Lipocine Inc. changed its name from Marathon Bar Corp on November 30, 2011.
Where are Lipocine Inc.'s principal executive offices located?
Lipocine Inc.'s principal executive offices are located at 675 Arapeen Drive, Suite 202, Salt Lake City, Utah.
What is the Commission File Number for Lipocine Inc.?
The Commission File Number for Lipocine Inc. is 001-36357.
Does this filing indicate any specific new product development or regulatory approval for Lipocine Inc.?
This filing does not specify any new product development or regulatory approvals; it is categorized under 'Other Events' and 'Financial Statements and Exhibits'.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 9, 2025 regarding Lipocine Inc. (LPCN).